# Sun Pharma Advanced Research Company trials: 35 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 35 trials with Sun Pharma Advanced Research Company Limited as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Sun Pharma Advanced Research Company Limited: 35 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sun-pharma-advanced-research-company-limited

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 35
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 35, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07923734 | Study of Electrocardiogram (ECG) Safety of Sezaby in Neonatal Seizures | Sun Pharma Advanced Research Company Limited | Phase 4 | Not yet recruiting | Neonatal Seizure | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923734) |
| April 8, 2026 | NCT07517315 | Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to... | Sun Pharma Advanced Research Company Limited | Not applicable | Temporarily not available | CML, Relapsed, CML, Refractory | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517315) |
| June 27, 2025 | NCT07042100 | A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. | Sun Pharma Advanced Research Company Limited | Phase 1 | Recruiting | Advanced Solid Tumors | 177 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07042100) |
| June 28, 2021 | NCT04942054 | A Study in Patients With Advanced Breast Cancer | Sun Pharma Advanced Research Company Limited | Phase 1 | Terminated | HER2-negative Breast Cancer, Advanced Breast Cancer, Hormone Receptor-positive Breast Cancer | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04942054) |
| April 2, 2020 | NCT04332549 | To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or... | Sun Pharma Advanced Research Company Limited | Phase 1 | Withdrawn | Metastatic Breast Cancer, Locally Recurrent Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04332549) |
| January 27, 2020 | NCT04242953 | Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects | Sun Pharma Advanced Research Company Limited | Phase 1 | Completed | Healthy Volunteer Study | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04242953) |
| August 31, 2018 | NCT03655236 | PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using... | Sun Pharma Advanced Research Company Limited | Phase 2 | Terminated | Early Parkinson Disease | 513 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03655236) |
| June 26, 2018 | NCT03567941 | To Evaluate the Relative Abuse Potential of Hydrocodone Bitartrate and Acetaminophen | Sun Pharma Advanced Research Company Limited | Phase 1 | Completed | Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03567941) |
| March 1, 2018 | NCT03450629 | Evaluation of Safety and Efficacy of PDP-716 | Sun Pharma Advanced Research Company Limited | Phase 3 | Completed | Open Angle Glaucoma, Ocular Hypertension | 682 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03450629) |
| February 26, 2018 | NCT03445338 | To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers | Sun Pharma Advanced Research Company Limited | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03445338) |
| February 8, 2018 | NCT03426267 | Evaluation of Efficacy and Safety of SDN-037 | Sun Pharma Advanced Research Company Limited | Phase 3 | Completed | Inflammation and Pain Associated With Ocular Surgery | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03426267) |
| October 20, 2017 | NCT03316820 | Bioavailability Study of K0706 in Healthy Subjects | Sun Pharma Advanced Research Company Limited | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03316820) |
| April 12, 2017 | NCT03109249 | Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer | Sun Pharma Advanced Research Company Limited | Phase 1 | Completed | Recurrent or Metastatic Breast Cancer | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03109249) |
| February 16, 2017 | NCT03055143 | Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer | Sun Pharma Advanced Research Company Limited | Phase 1 | Completed | Breast Cancer and Ovarian Cancer | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03055143) |
| December 13, 2016 | NCT02991261 | Bioavailability Study of SPARC001 (Study 2) in Healthy Adult Volunteers | Sun Pharma Advanced Research Company Limited | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02991261) |
| December 13, 2016 | NCT02991222 | Bioavailability Study of SPARC001(Study 1) in Healthy Adult Volunteers | Sun Pharma Advanced Research Company Limited | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02991222) |
| November 21, 2016 | NCT02970019 | Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease | Sun Pharma Advanced Research Company Limited | Phase 1 | Completed | Parkinson Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02970019) |
| September 2, 2016 | NCT02887534 | Evaluation of Efficacy and Safety of SPARC1401 in Acute Low Back Pain | Sun Pharma Advanced Research Company Limited | Phase 2 | Withdrawn | Acute Muscle Pain | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02887534) |
| December 14, 2015 | NCT02629692 | Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies | Sun Pharma Advanced Research Company Limited | Phase 1/2 | Terminated | Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C) | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02629692) |
| December 1, 2015 | NCT02618395 | Bioavailability Study of SPARC001 in Healthy Adult Volunteers | Sun Pharma Advanced Research Company Limited | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02618395) |
| November 5, 2015 | NCT02597465 | A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 | Sun Pharma Advanced Research Company Limited | Phase 3 | Withdrawn | Advanced Biliary Tract Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02597465) |
| May 13, 2014 | NCT02136927 | Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast Cancer | Sun Pharma Advanced Research Company Limited | Phase 1 | Terminated | Breast Cancer | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02136927) |
| January 20, 2014 | NCT02041221 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316 | Sun Pharma Advanced Research Company Limited | Phase 1/2 | Completed | Asthma | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02041221) |
| January 3, 2014 | NCT02027025 | Study of SPARC1103 in Subjects With Spasticity | Sun Pharma Advanced Research Company Limited | Phase 2 | Completed | Spasticity | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02027025) |
| September 12, 2013 | NCT01940146 | Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis | Sun Pharma Advanced Research Company Limited | Phase 2 | Completed | Seasonal Allergic Rhinitis | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01940146) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 18 |
| Phase 1/2 | 2 |
| Phase 2 | 6 |
| Phase 3 | 7 |
| Phase 4 | 1 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 25 |
| Terminated | 4 |
| Withdrawn | 3 |
| Not yet recruiting | 1 |
| Temporarily not available | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 4 |
| Muscle Spasticity | 3 |
| Glaucoma, Open-Angle | 3 |
| Ocular Hypertension | 3 |
| Neoplasms | 2 |
| Ovarian Neoplasms | 2 |
| Recurrence | 2 |
| Parkinson Disease | 2 |
| Carcinoma | 1 |
| Rhinitis, Allergic | 1 |
| Glaucoma | 1 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 |
| Asthma | 1 |
| Inflammation | 1 |
| Multiple Sclerosis | 1 |
| Rhinitis, Allergic, Seasonal | 1 |
| Conjunctivitis, Allergic | 1 |
| Multiple Myeloma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Theme restaurants in the United States](https://specstream.ai/data/businesses/theme-restaurants/united-states)
- [Indian restaurants in the United States](https://specstream.ai/data/businesses/indian-restaurants/united-states)
- [B2B oil and gas equipment companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-equipment-companies/united-states)
- [Paralegal companies in the United States](https://specstream.ai/data/businesses/paralegal-companies/united-states)
- [Dental clinics in the United States](https://specstream.ai/data/businesses/dental-clinics/united-states)
- [Sri Lankan restaurants in the United States](https://specstream.ai/data/businesses/sri-lankan-restaurants/united-states)
